All In Biotech

Drug Trial Radar · NCT06569355

A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VCT220 Tablets in Overweight/Obese Subjects

Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

250

Actual

Start

Dec 27, 2023

Primary completion

Jul 13, 2024

Study completion Aug 1, 2024

Sponsor

Lead sponsor
Vincentage Pharma Co., LtdIndustry
Sponsor type
Industry
First posted
Aug 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the study is to assess how VCT220 tablets affect the bodyweight when used once daily in obese or overweight adult participants Qualified participants will be randomly assigned to one of four groups using a computerized system. Participants will get VCT220 or placebo tablets for 16 weeks and will need to take tablets each morning. Participants will have 7 clinic visits and a final follow-up visit approximately 14 days after the last study intervention administration.

Conditions

  • Obesity
  • Overweight

Interventions

  • VCT220Drug

    A small molecule GLP-1R agonist tablet, orally administration, once daily

  • PlaceboDrug

    Placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in body weightTime frame: From baseline (week 1) to week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.